杨尚文,邵明冉,杨献峰,胡安宁,王钟,蒋辉,朱斌,张冰,辛小燕.“三低”技术联合全模型迭代重建算法在头颈部CT血管成像中的可行性研究[J].中华放射医学与防护杂志,2017,37(1):62-67
“三低”技术联合全模型迭代重建算法在头颈部CT血管成像中的可行性研究
A feasibility study on “Tri-Low” technology in combination with iterative model reconstruction(IMR) algorithm in CT angiography(CTA) of the head-and-neck vessels
投稿时间:2016-08-04  
DOI:10.3760/cma.j.issn.0254-5098.2017.01.012
中文关键词:  血管成像  体层摄影术,X射线计算机  辐射剂量  迭代重建
英文关键词:Angiography  Tomography, X-ray computed  Radiation dose  Iterative reconstruction
基金项目:江苏省卫生厅青年科研课题(Q201410)
作者单位
杨尚文 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
邵明冉 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
杨献峰 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
胡安宁 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
王钟 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
蒋辉 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
朱斌 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
张冰 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
辛小燕 210008 江苏, 南京大学医学院附属鼓楼医院医学影像科 
摘要点击次数: 3435
全文下载次数: 2099
中文摘要:
      目的探讨80 kV低管电压、低对比剂注射速率和低对比剂用量的“三低”技术,联合全模型迭代重建(IMR)算法在头颈部CT血管成像(CTA)检查的可行性。方法前瞻性连续收集2015年7-11月行头颈部CTA检查的患者60例,采用随机数字表法将其分为A、B两组,每组各30例。A组为常规剂量组,管电压120 kV,滤过反投影(FBP)重建,对比剂注射速率4.5~5.5 ml/s,注射时间10 s;B组为80 kV低管电压组,分别使用FBP和IMR进行图像重建,得到B1和B2两组图像,对比剂注射速率3.5~4.0 ml/s,注射时间10 s。测量并计算A组、B1组、B2组的图像动脉血管CT值、图像噪声、信噪比(SNR)和对比噪声比(CNR),并由2名放射诊断医师对图像质量按照5分法进行评价。3组图像间动脉血管CT值、图像噪声、SNR和CNR采用单因素方差分析,图像质量主观评价采用Kruskal-Wallis检验,两组检查的容积CT剂量指数(CTDIvol)和剂量长度乘积(DLP)比较采用两个独立样本t检验。结果 A、B1和B2组3组图像质量主观评分范围分别为3~5分、2~4分和3~5分,B1组有12例患者图像之间评分≤2分,图像无法诊断。A和B1、A和B2、B1和B2图像之间评分差异均有统计学意义(t=4.55、-6.58、-2.03,P<0.05)。B2组与A组的图像客观指标SNR和CNR比较差异无统计学意义(P>0.05),但B2和A组图像的SNR、CNR均优于B1组,差异均有统计学意义(t=-12.14、13.39、-9.96、9.45,P<0.05)。B组CTDIvol[(1.7±0.2)mGy]比A组[(8.9±1.0)mGy]减少了80.9%,DLP[(77.9±9.0)mGy·cm]比A组[(415.5±56.7)mGy·cm]减少了81.3%,B组对比剂注射速率[(3.9±0.1)ml/s]比A组[(5.0±0.2)ml/s]减少了22.0%,B组对比剂总量[(39.2±1.9)ml]比A组[(50.3±2.2)ml]减少22.1%,差异有统计学意义(t=39.1、32.2、20.8、20.8,P<0.05)。结论使用80 kV管电压、低对比剂注射速率和用量,并使用IMR算法进行图像重建,进行头颈部CTA扫描是可行的。可以在保证图像质量的基础上,使患者辐射剂量减少81.3%。临床试验注册号中国临床试验注册中心,ChiCTR-BOC-16010060。
英文摘要:
      Objective To evaluate the feasibility of low-tube-voltage,low injection rate,low contrast agent dosage in combination with iterative model reconstruction(IMR) algorithm in CT angiography(CTA) of the head-and-neck vessels.Methods Sixty patients who underwent CT angiography of the head-and-neck vessels were randomly divided into groups A and B with 30 cases in each group. Patients in group A received a conventional scan with 120 kVp and filterback projected(FBP) reconstruction. Patients in group B received a low-dose scan with 80 kVp, and image reconstruction with FBP(group B1) and IMR(group B2) algorithm. The contrast agent protocol were as follows:the injection time in all patients was 10s, the injection rate was 4.5-5.5 ml/s in group A while 3.5-4.0 ml/s in group B. The CT values of artery, image noise, signal to noise ratio(SNR) and contrast to noise ratio(CNR) were measured and compared among three groups with One-way ANOVA analysis. Image quality was evaluated by two radiologists with five scale method, and compared with Kruskal-Wallis test. The CT dose index volume (CTDIvol) and dose length product (DLP) were recorded and compared between groups with two independent samples t-test. Results The image quality scores of groups A, B1and B2 were 3-5, 2-4 and 3-5, respectively.Image quality of twelve patients in group B1 couldn't meet the diagnostic requirements but none in group A and B2.The objective image parameters SNR and CNR for group B2 were equal to group A(P>0.05), while those for group B1 were lower than group A(t=13.39, 9.45,P<0.05) and group B2(t=-12.14, -9.96, P<0.05). CTDIvol and DLP for group B were separately 80.9%, 81.3% lower than those of group A(t=39.1, 32.2, P<0.05). The injection rate and contrast agent volume for group B were separately 22.0%, 22.1% lower than those of group A(t=20.8, 20.8, P<0.01).Conclusions It is feasible in CT angiography of the head-and-neck vessels with lower tube-voltage, lower injection rate, lower contrast agent dose and combining with iterative model reconstruction algorithm. This protocol can reduce the radiation dose by 81.3% while maintaining image quality.Trial registration Chinese clinical trial registry,ChiCTR-BOC-16010060.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭